Cargando…
Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has...
Autores principales: | Andrés-Guerrero, Vanessa, Perucho-González, Lucía, García-Feijoo, Julián, Morales-Fernández, Laura, Saenz-Francés, Federico, Herrero-Vanrell, Rocío, Júlvez, Luis Pablo, Llorens, Vicente Polo, Martínez-de-la-Casa, José María, Konstas, Anastasios-Georgios P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331081/ https://www.ncbi.nlm.nih.gov/pubmed/28000166 http://dx.doi.org/10.1007/s12325-016-0461-z |
Ejemplares similares
-
Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Considerations
por: Andrés-Guerrero, Vanessa, et al.
Publicado: (2017) -
Evaluation of a Novel Αb Εxterno MicroShunt for the Treatment of Glaucoma
por: Burgos-Blasco, Barbara, et al.
Publicado: (2022) -
Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
por: Martínez-de-la-Casa, José M., et al.
Publicado: (2021) -
Influence of Sex on Neuroretinal Degeneration: Six-Month Follow-Up in Rats With Chronic Glaucoma
por: Rodrigo, Maria J., et al.
Publicado: (2021) -
Management of exfoliative glaucoma: challenges and solutions
por: Holló, Gábor, et al.
Publicado: (2015)